Clinical Development Programme
Besides the SCOUT and NAVIGATE clinical trials that supported the registration of larotrectinib and which are still ongoing, larotrectinib has also been included in two ongoing independent National Cancer Institute (NCI)-supported clinical trials (NCI-MATCH and NCI-COG Pediatric MATCH) that are screening and treating patients based on genetic alterations in their tumours rather than based on tumour-type [1].
Key Ongoing Larotrectinib Clinical Trials
Registry Number |
Name |
Phase |
Title |
|---|---|---|---|
NCT03213704 |
Pediatric MATCH Treatment Trial |
2 |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions |
NCT02465060 |
MATCH Screening Trial |
2 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma |
References
- Lassen UN, Albert CM, Kummar S et al. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. Annals of Oncology 2018; 29: mdy279.397-mdy279.397.